neurology
Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale
Patient-reported outcome measure assessing myasthenia gravis symptom severity across 8 functional domains. Validated tool for monitoring treatment response and disease progression.
References
- Wolfe GI et al. Myasthenia Gravis Activities of Daily Living profile. Neurology. 1999;52(7):1487-1489.
- NICE NG217. Myasthenia gravis: treatment algorithm and specialist referral criteria. 2022.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Exenatide · GLP-1 Receptor Agonist
- Pyridostigmine · Acetylcholinesterase Inhibitor — Myasthenia Gravis
- Esketamine · NMDA Receptor Antagonist (Treatment-Resistant Depression / Acute Suicidality)
- Naftidrofuryl Oxalate · 5-HT2 Receptor Antagonist — Peripheral Arterial Disease (Intermittent Claudication)
- Cisatracurium · Neuromuscular Blocking Agent (Non-Depolarising)
- Atracurium · Non-Depolarising Neuromuscular Blocking Agent
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.